

# NEW BIOMEDICINE


## R E S E A R C H

biotechnology research report

### Top 10 Small Cap. Biotech Performers: April 7, 2010 – May 7, 2010

Tickers	AEZS, RPTP, CPRX, JAV, CPEX, AKRX, KERX, PRWP, CUR, INHX	Updated:	05/10/2010
		By:	Michael Engmann

- 1) **Company:** AEterna Zentaris (AEZS - \$1.68)  
**Market Cap. :** \$124M  
**1 Month Performance:** + 96%  
**Drivers:** Company receives Orphan-Drug designation from FDA for ovarian cancer drug. - *May 6, 2010*. Company completes \$15M stock offering. - *April 20, 2010*
- 2) **Company:** Raptor Pharmaceuticals (RPTP - \$3.07)  
**Market Cap. :** \$201M  
**1 Month Performance:** + 78%  
**Drivers:** Company report positive Phase II results for cysteamine treatment of the liver. - *May 3, 2010*
- 3) **Company:** Catalyst Pharmaceuticals (CPRX - \$1.23)  
**Market Cap. :** \$22M  
**1 Month Performance:** + 70%  
**Drivers:** Company signs Phase II Clinical Trial Agreement with the National Institute on Drug Abuse to treat cocaine addiction. - *April 13, 2010*
- 4) **Company:** Javelin Pharmaceuticals (JAV - \$2.18)  
**Market Cap. :** \$140M  
**1 Month Performance:** + 64%  
**Drivers:** Hospira agrees to buy Company for \$2.20/share. - *April 19, 2010*
- 5) **Company:** CPEX Pharmaceuticals (CPEX - \$25.25)  
**Market Cap. :** \$64M  
**1 Month Performance:** + 62%  
**Drivers:** RSR Acquisition Co. announces commencement of \$16/share offer for Company. - *April 23, 2010*



# NEW BIOMEDICINE RESEARCH

## biotechnology research report

- 6) **Company:** Akorn (AKRX - \$2.39)  
**Market Cap. :** \$220M  
**1 Month Performance:** + 60%  
**Drivers:** Company gets FDA approval for ANDA for Erythromycin Ophthalmic Ointment. - *April 21, 2010*
- 7) **Company:** Keryx Biopharmaceuticals (KERX - \$5.32)  
**Market Cap. :** \$302M  
**1 Month Performance:** + 60%  
**Drivers:** Company releases data on preclinical on neuroblast, the company's novel, potentially first-in-class oral anti-cancer agent. - *April 21, 2010*
- 8) **Company:** Pro-Pharmaceuticals (PRWP - \$0.66)  
**Market Cap. :** \$34M  
**1 Month Performance:** + 46%  
**Drivers:** Company announces its management met with Columbia President to discuss improving chemotherapy treatment with their drug.
- 9) **Company:** Neuralstem (CUR - \$2.90)  
**Market Cap. :** \$124M  
**1 Month Performance:** + 45%  
**Drivers:** CNN highlights Company's Phase I stem cell treatment program for ALS. - *April 30, 2010*. Positive comments from lead investigator in trial. - *May 2, 2010*
- 10) **Company:** Inhibitex (INHX - \$2.22)  
**Market Cap. :** \$136M  
**1 Month Performance:** + 44%  
**Drivers:** Company announces positive interim results for Phase II clinical trial for shingles pain. - *April 12, 2010*

